15 results about "Symptom Cluster" patented technology

The present invention relates to a composition comprising eptinezumab and LuAG09222. This composition may be used, for example, to treat or prevent headache, pain, migraine, cluster headache, or endometriosis.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The invention relates to the field of medical instruments, in particular to an oxygen inhalation device for treating cluster headache, which comprises a shell and a controller, the top of the shell is communicated with an air outlet pipe, and one end, far away from the shell, of the air outlet pipe is communicated with a breathing mask; a purification mechanism, an amplification mechanism and a linkage mechanism are arranged in the shell, and the purification mechanism is used for separating and purifying oxygen from ambient air; the amplifying mechanism is used for pressurizing the oxygen output by the purifying mechanism and outputting the oxygen to the breathing mask. The linkage mechanism is used for converting the switching power of the amplifying mechanism into movement for driving the purification mechanism to periodically switch, so that the switching period of the purification mechanism is synchronous with the gas supply period of the amplifying mechanism, and the adsorption and desorption flow switching of the purification mechanism is realized. Cooperative utilization of energy is achieved through the linkage mechanism, and the energy efficiency of equipment is improved; the amplification mechanism drives the purification mechanism to periodically switch, so that the secondary conversion loss of energy is reduced; the dependence on external power energy is reduced, the economic pressure can be reduced, and the treatment sustainability is improved.

The present invention relates to compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4- (trifluoromethoxy)benzyl] amino }sulfonyl)benzoic acid (elismetrep; MT-8554), or a pharmaceutically acceptable salt thereof, for treating or preventing pain, particularly migraine or a trigeminal pain disease or condition such as medication overuse headache, cluster headache, general headache, trigeminal neuralgia, trigeminal neuropathy, trigeminal autonomic cephalalgia, orofacial pain, and dental pain.

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

This article discloses a lipid prodrug of bromo-lysergic acid diethylamide (2-bromo-LSD) (2-bromo-lysergic acid diethylamide), which achieves improved pharmacokinetic properties and allows for easier long-term administration to patients. The disclosed lipid prodrug is indicated for the treatment of cluster headaches and mood disorders in human subjects.

The application discloses a postoperative symptom group trajectory prediction method and system based on multi-source data, relates to the technical field of postoperative management of colorectal cancer, and comprises the following steps: obtaining a unique identity identifier and static physiological characteristics of a target patient, querying a historical evolution trend and a historical intervention trajectory of a postoperative symptom group of the target patient according to the unique identity identifier; obtaining a target intervention measure; and inputting the static physiological characteristics, the historical evolution trend, the historical intervention trajectory and the target intervention measure into a pre-trained trajectory prediction model to generate an expected evolution trend of a target symptom, so that a technical transformation from single-time risk prediction to continuous trajectory prediction for auxiliary decision-making is realized.

The present invention relates to a composition comprising an epnuclizumab and LuAG09222, and to a method for preparing the same. The composition may be used to treat or prevent, for example, headache, pain, migraine, cluster headache or endometriosis.

Compositions and methods for preventing or reducing the occurrence of headache disorders in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a nontoxic engineered protein derived from a botulinum toxin complex. The headache disorder may be selected from episodic migraine headaches, tension-type headaches, cluster headaches, hemiplegic migraine headaches, or retinal migraine headaches.

The invention discloses an aryl-substituted cyclic amine compound as well as a preparation method and application thereof. The invention provides an application of a substance Z or a pharmaceutical composition containing the substance Z in preparation of a serotonin 5-HT2A receptor agonist. The substance Z is a compound as shown in a formula I, a pharmaceutically acceptable salt, a prodrug, a solvate, a deuterated substance or a stereoisomer thereof, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier. The compound provided by the invention can be used for preventing and treating depression, anxiety, cluster headache or neurodegenerative diseases.

This invention belongs to the field of rehabilitation medicine technology, specifically disclosing an intelligent triage assessment system and method for F-S-D symptom clusters in breast cancer chemotherapy patients. The system includes: a multi-dimensional data acquisition module configured to acquire real-time sensory intensity data of the patient for three dimensions: fatigue, sleep disturbance, and depression, and map them into standardized symptom intensity vectors; a dynamic threshold determination module configured to determine whether to enable a fixed threshold or a dynamic threshold, and calculate a personalized dynamic threshold when enabling a dynamic threshold; a core symptom determination module configured to determine the patient's current core symptoms using a recursive decision tree; and a specialized assessment scale loading module configured to retrieve specialized assessment scales for core symptoms from the cloud for the patient to complete, and generate a structured report with severity gradients based on the completion results. This invention eliminates the need for full-scale quantitative assessment, making the testing process more targeted and reducing the workload of the assessment.

In some aspects, pharmaceutical compounds are disclosed which may be useful for treating anxiety and / or other disorders. In another aspect, a pharmaceutical composition includes a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle therefor. In yet another aspect, a method of treating anxiety, depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, cluster headache, or cancer-related or other end-of-life psychological distress involves administering the pharmaceutical composition to an individual in need thereof.

Disclosed in the present invention are a cyclic amine compound with an aryl substitution, and a preparation method therefor, and a use thereof. The present invention provides the use of a substance Z or a pharmaceutical composition comprising the substance Z in the preparation of a serotonin 5-HT2A receptor agonist, the substance Z being a compound of formula I, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a deuterated derivative thereof, or a stereoisomer thereof. The pharmaceutical composition further comprises a pharmaceutically acceptable carrier. The compounds of the present invention can be used for preventing and treating depression, anxiety, cluster headaches, or neurodegenerative diseases.

Providing compositions and methods for targeting inflammatory cells or activated cells to treat or improve inflammatory conditions and pain. [Solution] A method is provided for modifying the amino acid sequence and increasing the expression level of ApoA-I binding protein for treating neuropathic pain, CNS inflammation, allodynia, post-neuropathy pain, postoperative pain, chemotherapy-induced peripheral neuropathy, neurodegenerative diseases or conditions such as Alzheimer's disease, hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory eye diseases, pneumonia, asthma, HIV infection, vasculitis, atherosclerosis and cardiovascular diseases.